Summary of SCNI Q2 2024 Earnings Call

1Key Financial Results and Metrics

R&D Expenses: $2.79 million for the first half of 2024, down from $3.45 million in 2023, attributed to salary reductions and less subcontractor use.

Marketing and G&A Expenses: $1 million for H1 2024, decreased from $2.3 million in the previous year.

Financial Expenses: Reduced to $0.53 million from $1.5 million in H1 2023, due to a reclassification of warrants and loan revaluation.

Net Loss: $4.48 million for H1 2024, improved from $7.28 million in H1 2023.

Cash Position: $3.21 million as of June 30, 2024, down from $7.63 million a year prior.

Shareholder Equity: Expected to be negative $7.28 million, but anticipated to improve to approximately $12 million positive post-EIB restructuring.

2Strategic Updates and Business Highlights

R&D Pipeline: Focus on developing nanoAbs for autoimmune and infectious diseases, with promising preclinical results for SCN-1, targeting IL-17 in plaque psoriasis.

CDMO Business Unit: Generated $600,000 in work orders since January 2024, with a target of $1.25 million in revenue for 2024. Plans to expand services to Europe and the U.S.

Regulatory Progress: Positive feedback from the Paul Erlich Institute regarding the clinical trial for SCN-1, allowing for a more streamlined approval process.

Investment Commitment: Secured a $2 million equity commitment from Daniel Stone, which will support operations through 2024.

3Forward Guidance and Outlook

Clinical Trials: Phase 1/2a trial for SCN-1 expected to start in H2 2025, with readouts anticipated in 2026.

Revenue Growth: CDMO revenues expected to increase significantly as the unit ramps up operations, with a potential capacity of $24 million annually in the long term.

Strategic Partnerships: Plans to engage larger pharma companies for potential licensing and commercialization deals to mitigate risks and enhance cash flow.

4Bad News, Challenges, or Points of Concern

Cash Burn: Despite a reduction in losses, the cash position has decreased significantly year-over-year, raising concerns about liquidity.

Negative Shareholder Equity: Current negative equity position could deter potential investors until the EIB restructuring is completed.

Market Competition: The biotechnology sector remains competitive, and Scinai must differentiate its offerings to capture market share effectively.

5Notable Q&A Insights

Long-term Vision: CEO Amir Reichman emphasized the company's undervaluation and potential for growth, citing a robust pipeline and strategic positioning in the market.

Regulatory Strategy: The company is focused on a streamlined regulatory approach to expedite clinical trials and reduce costs.

Future of CDMO: The CDMO unit is seen as a vital revenue stream and a way to enhance R&D capabilities, providing a competitive edge in the biotech landscape. Overall, Scinai Immunotherapeutics is navigating a challenging financial landscape while making strides in its R&D and CDMO operations, with a focus on strategic partnerships and regulatory efficiencies to drive future growth.